middle.news

CSL Delivers Steady Growth, Reaffirms FY25 Earnings Guidance

9:05am on Monday 2nd of June, 2025 AEST Pharmaceuticals
Read Story

CSL Delivers Steady Growth, Reaffirms FY25 Earnings Guidance

9:05am on Monday 2nd of June, 2025 AEST
Key Points
  • 5% revenue growth to US$8.47 billion at constant currency
  • 7% increase in net profit after tax (NPAT) to US$2.04 billion
  • Strong performance in CSL Behring and Vifor segments
  • Seqirus segment impacted by low immunisation rates and competitive pressures
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about CSL (ASX:CSL)
OPEN ARTICLE